Highlights ASCO 2015, Prostaatkanker STAMPEDE #ASCO2015


De onderzoeksresulaten van STAMPEDE overtreffen die van CHAARTED. Met zes kuren docetaxel is is het overlevingsvoordeel van 10 maanden in de gehele onderzochte groep  significant. In de groep uitgezaaide ziekte is zelfs een winst van maar liefst 22 maanden ten opzichte van hormoontherapie alleen.

Het doel van de STAMPEDE trial is om hergroei van de tumorte voorkomen door toevoeging van een andere behandeling dan hormoontherapie.
Overleving en dan met name failure-free survival (FFS), blijft relatief een slecht te realiseren doel voor mannen. Een betere eerstelijn therapie is daarom nodig; STAMPEDE laat dit duidelijk zien. De Stampede studie, is een opnieuw bewezen Britse therapie die nu in Nederland de standaardbehandeling lijkt te gaan worden. De behandeling –  zes kuren chemo met hormoontherapie- die de patiënt een extra overlevingstijd van gemiddeld twee jaar geeft, zal zeker een verandering geven in de richtlijn voor de behandeling van prostaatkanker.

Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: Data from >600 patients in the control arm of the STAMPEDE trial (NCT00268476).

Session Type and Session Title:
Poster Discussion Session, Genitourinary (Prostate) Cancer
Abstract Number: 5012
Citation: J Clin Oncol 31, 2013 (suppl; abstr 5012)
Noel W Clarke, Nicholas David James, Malcolm David Mason, Daniel M. Aebersold, David Paul Dearnaley, Johann Sebastian De Bono, Chris Parker, Mahesh Parmar, Alastair WS Ritchie, J. Martin Russell, Melissa Ruth Spears, George N. Thalmann, Matthew Robert Sydes, STAMPEDE Investigators; Department of Urology, The Christie NHS Foundation Trust, Manchester, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Cardiff University, Cardiff, United Kingdom; University of Bern, Bern, Switzerland; Institute of Cancer Research/Royal Marsden Hospital, Sutton, United Kingdom; The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Department of Urology, University Hospital, Bern, Switzerland

Abstracts that were granted an exception in accordance with ASCO’s Conflict of Interest Policy are designated with a caret symbol (^).

Background: STAMPEDE (www.stampedetrial.org) recruits men with newly-diagnosed or rapidly relapsing prostate cancer (PCa) that is metastatic (M1) or high-risk locally advanced, all commencing long-term androgen ablation therapy (AAT) for the first time. This is now the largest therapeutic RCT in PCa. We report survival outcomes for newly-diagnosed M1 control arm men in order to inform future trials in this setting.

Methods: Newly-diagnosed men with M1 disease in the trial’s control arm (standard of care: AAT alone for at least 2yr), diagnosed up to 6 months prior to randomisation, were identified from trial records in Dec-2012. We report overall survival (OS) and failure-free survival (FFS) from randomisation by primary disease characteristics.

Results: 3703 men were recruited to STAMPEDE Oct-2005 to Dec-2012, including a control arm cohort of 630 M1 men with newly-diagnosed disease. This cohort has median age at randomisation 66yr (quartiles 60-71), median PSA 105 (quartiles 34-379) IU/l; metastases to bone only (B) 393 (62%), soft tissue only (ST) 78 (13%) or bone and soft tissue (B+ST) 159 (25%). ST was mainly lymph nodes. Median time from diagnosis to randomisation is 69 days (max 180 days). Median duration of AAT prior to randomisation is 46 days (max 105 days). There were 129 deaths, of which 111 were from PCa. Median OS from randomisation is 42 months, with 2-yr OS 74% (95%CI 68, 78) in this cohort; B 77% (95%CI 71, 83), ST 85% (95%CI 70, 93), B+ST 57% (95%CI 45, 68). Median FFS is 12 months, driven by rising PSA; 2-yr FFS 32% (95%CI 27-37). Median time from FFS event to death was 22 months. Additional data on relapse therapies will be presented.

Conclusions: Survival, and particularly FFS, remains relatively poor for men presenting with M1 disease starting long-term AAT, despite potential access when castration-resistant (CRPC) to docetaxel and other newer therapies. Better first-line therapy is required; STAMPEDE will report many comparisons in the future. Different M1 patterns may vary prognostically. Men with M1 disease will now spend most time in a state of CRPC, which has important implications for clinicians and trialists. Clinical trial information: NCT00268476.

Abstract Disclosures

  1. Meeting: 2015 Genitourinary Cancers Symposium | Abstract No: 368 | First Author: Syed A. Hussain

  2. Meeting: 2015 ASCO Annual Meeting | Abstract No: e16108 | First Author: Nicholas David James

  3. Meeting: 2015 ASCO Annual Meeting | Abstract No: 5001 | First Author: Nicholas David James